ArticleMuscle & nerve2026
Whole Body Phase Angle as a Promising Marker of Disease Severity in Facioscapulohumeral Muscular Dystrophy.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
INTRODUCTION/
aimsTo investigate its potential role as a marker of disease severity in facioscapulohumeral dystrophy (FSHD), this study examined the association between whole-body phase angle (PhA) and clinically assessed severity in FSHD patients.
methodsPatients were evaluated for PhA using bioelectrical impedance analysis (BIA) and for disease severity using the FSHD clinical score. In a subgroup, physical activity level (PAL) was assessed using a questionnaire. Pearson correlations were performed in the total cohort and PAL-assessed subgroup, stratified by sex and clinical phenotype (category A and non-A) according to the Comprehensive Clinical Evaluation Form. Multivariate regression analyses were conducted adjusting for age, body mass index, and PAL. Due to the small sample, correlation was not performed in PAL-assessed non-A patients, while multivariate regression was not performed in non-A patients and PAL-assessed stratified subgroups.
resultsSeventy-two patients (mean age 39.94 ± 17.52 years; 27 females and 45 males; 58 category A and 14 non-A) were enrolled. The PAL-assessed subgroup comprised 38 patients (mean age 41.39 ± 14.98 years; 16 females and 22 males; 31 category A and 7 non-A). Pearson analyses revealed that PhA was inversely associated with clinical score in all groups (r -0.63 to -0.84, p 0.02 to < 0.001). Multivariate regression confirmed PhA as the sole independent predictor across all groups (β = -0.64 to -0.93, all p < 0.001). DISCUSSION: These results support the potential role of PhA as a marker of disease severity in FSHD. Longitudinal studies are warranted to determine its sensitivity for monitoring disease progression over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.